Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 10/20 | 0.53 |
| ▸ | CES1 | P23141 | 10/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6969664 | 0.84 | EGFR (0.45) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL1912788 | 0.83 | CES2 (0.58) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL649673 | 0.83 | CES2 (0.58) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL11876720 | 0.79 | CES2 (0.59) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL11876725 | 0.79 | CES2 (0.59) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL5216998 | 0.79 | CES2 (0.50) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL5216994 | 0.79 | CES2 (0.50) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL9874158 | 0.79 | CYP11B1 (0.54) | CES2CES1 | |
| SCHEMBL28825861 | 0.78 | CES2 (0.57) | CES2CES1EGFRRAB9ALMNA | |
| SCHEMBL10062280 | 0.78 | CES2 (0.57) | CES2CES1EGFRRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | CES2 4641/4885CES1 3519/4885EGFR 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.